Iria Torres-Terán

Iria Torres-Terán

Auto-generated profile, based on publicly available information

Iria Torres-Terán

University of Greifswald. Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, 3 Felix Hausdorff Street, 17489 Greifswald, Germany; Sanofi-Aventis Deutschland GmbH, R&D, Global CMC Development, Synthetics Platform. Industriepark Hoechst, H770, D-65926 Frankfurt am Main, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ITIria Torres-Terán
Iria Torres-Terán
MVMárta Venczel
Márta Venczel
TSTatjana Stieler
Tatjana Stieler
LPLaura Parisi
Laura Parisi
AKAlla Kloss
Alla Kloss
SKSandra Klein
Sandra Klein

13 May 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
ITIria Torres-Terán
Iria Torres-Terán
MVMárta Venczel
Márta Venczel
SKSandra Klein
Sandra Klein
Media that mimic physiological fluids at the site of administration have proven to be valuable in vitro tools for predicting in vivo drug release, particularly for routes of administration where animal studies cannot accurately predict human performance. The objective of the present study was to develop simulated interstitial fluids (SISFs) that mimic the major components and physicochemical properties of subcutaneous interstitial fluids (ISFs) from preclinical species and humans, but that can be easily prepared in the laboratory and used in in vitro experiments to estimate in vivo drug release and absorption of subcutaneously administered formulations. Based on data from a previous characterization study of ISFs from different species, two media were developed: a simulated mouse-rat ISF and a simulated human-monkey ISF. The novel SISFs were used in initial in vitro diffusion studies with a commercial injectable preparation of liraglutide. Although the in vitro model used for this purpose still requires significant refinement, these two new media will undoubtedly contribute to a better understanding of the in vivo performance of subcutaneous injectables in different species and will help to reduce the number of unnecessary in vivo experiments in preclinical species by implementation in predictive in vitro models.